X-Chem Inc., a privately held biotechnology company focused on applying its drug discovery platform to the generation of novel small molecule therapeutics announced that Navitor Pharmaceuticals Inc., a biopharmaceutical company developing novel medicines by targeting cellular nutrient signaling, exercised its option to obtain an exclusive license to a series of small molecules targeting the activation of mTORC1, a key protein complex that orchestrates nutrient-mediated cellular metabolism and gr...